資源描述：
《替吉奧聯(lián)合多西他賽和順鉑治療進(jìn)展期胃癌的臨床觀察.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫(kù)。
1、·l58·實(shí)用癌癥雜志2013年3月第28卷第2期ThePracticalJournalofCancer，March2013，Vol28，No．2替吉奧聯(lián)合多西他賽和順鉑治療進(jìn)展期胃癌的臨床觀察邱國(guó)欽許麗貞林智才陳玉強(qiáng)崔殿龍【摘要】目的觀察替吉奧聯(lián)合多西他賽和順鉑(DCS方案)一線治療進(jìn)展期胃癌的有效性及安全性。方法采用隨機(jī)、對(duì)照、開(kāi)放性的臨床試驗(yàn)設(shè)計(jì)。入選96例初治的進(jìn)展期胃癌患者，隨機(jī)分為2組，治療組48例采用DCS方案化療：對(duì)照組48例．采用多西他賽、順鉑、亞葉酸鈣及氟尿嘧啶方案(DCF方案)化療；至少化療3個(gè)周期后評(píng)價(jià)療效及不良反應(yīng)。
2、結(jié)果治療組的近期有效率(RR)為83．3％，優(yōu)于對(duì)照組的54．2％，差異有統(tǒng)計(jì)學(xué)意義(P<0．05)；治療組中位rrP和MST分別為7．5個(gè)月和12．1個(gè)月，均高于對(duì)照組的5．6個(gè)月和8．4個(gè)月；治療組的不良反應(yīng)及嚴(yán)重反應(yīng)發(fā)生率均明顯低于對(duì)照組(P<0．05)。結(jié)論替吉奧聯(lián)合多西他賽和順鉑化療方案一線治療進(jìn)展期胃癌療效確切，不良反應(yīng)較少，患者耐受性良好。【關(guān)鍵詞】進(jìn)展期胃癌；化學(xué)治療；替吉奧；多西他賽；順鉑DOI：10．3969／j．issn．1001—5930．2013．02．015中圖分類號(hào)：R735．2文獻(xiàn)標(biāo)識(shí)碼：A文章編號(hào)：1001-
3、5930(2013)02-0158-03ClinicalObservationofS．1CombinedwithDocetaxelandCisplatinintheTreatmentofPatientswithAdvancedGastricCarcinomaQIUGuo—qin，XULi—zhen，L1NZhi—cai，eta1．DepartmetofOncology，ChenggongHospitalAffiliatedtoXiamenUniversity，the174HospitalofPeople&LiberationArmy，Xiam
4、en，361003【Abstract】ObjectiveToevaluatetheeficacyandsafetyofthecombinationofS-1withDocetaxelandCisplatin(DCStherapeuticregimens)asafirstlineregimeninthetreatmentofpatientswithadvancedgastriccarcinoma．MethodsArandom—ized，control，openclinicaltrialwasdesigned，96patientswithadva
5、ncedgastriccarcinomawererandomlydividedintotwogroups．Theexperimentalgroup(48patients)wastreatedbyusingtheDCStherapeuticschedules；thecontrolgroupwastreatedbyDoxt—axol，Cisplatin，CalciumFolinateand5-FU(DCFtherapeuticregimens)．Theshort—termeficacyandadversereactionswereeval—uat
6、edafteratleastthreetreatmentcycles．ResultsAllthe96patientsweresuitableforevaluation．Thetumorresponserate(RR)oftheexperimentalgroupwasbetterthanthatofthecontrolgroup(83．3％VS．54．2％，P<0．05)．Besides，themediantimetoprogression(MTI'P)andmediansurvivaltime(MST)were7．5monthsand12．1
7、monthsintheexperimentalgroup，whichwerelongerthanthatofthecontrolgroup(5．6and8．4months，respectively)．Inaddition，comparedwiththecontrolgroup．occurrencerateofadversereactionsandseriousresponseoftheexperimentalgroupweresignificantlylower(P<0．05)．ConclusionTheDCStherapeuticregim
8、enshoweddefinitecurativeeffectinthetreatmentofpatientswithadvancedgastricear—cinom
